First quarter total revenues of $244.3 million, up 19% year-over-year
- First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year
- First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped
- Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million
- Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025
https://www.businesswire.com/news/h...2025-Financial-Results-and-Operating-Overview
First quarter total revenues of $244.3 million, up 19%...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.44 |
Change
-0.480(3.72%) |
Mkt cap ! $1.547B | |||
| Open | High | Low | Value | Volume |
| $12.88 | $12.88 | $12.42 | $6.421M | 509.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1411 | $12.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.44 | 1692 | 2 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |